<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>佰傲谷BioValley | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2021-01-03T11:41:09+08:00</updated>
  <subtitle>佰傲谷致力于打造一个垂直于生物制品领域的第三方平台。为生物制药企业提供品牌推广、技术咨询、项目交易、企业合作、人才培养等服务。为生物制药行业从业人员提供沟通交流、会议培训、工作求职、个人展示平台</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>难逃此劫：百时美施贵宝（BMS）宣布撤出O药小细胞肺癌美国市场</title>
    <updated>2021-01-03T09:13:22+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-03:/s/hjp9vQt36lajGytXiBL8FA</id>
    <link href="https://mp.weixin.qq.com/s/hjp9vQt36lajGytXiBL8FA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>靶点药讯42|纵览全球药物靶点动态</title>
    <updated>2021-01-03T09:13:22+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-03:/s/MEa-6FWl5_vDHuOuisEIGg</id>
    <link href="https://mp.weixin.qq.com/s/MEa-6FWl5_vDHuOuisEIGg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>开年钜献！干货集结：专攻细胞基因免疫治疗技术！</title>
    <updated>2021-01-03T09:13:22+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-03:/s/uQxjxNWpmGxOiVl7ulh4tw</id>
    <link href="https://mp.weixin.qq.com/s/uQxjxNWpmGxOiVl7ulh4tw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020 Think Big 十佳入选项目专访 | 荣瑞医药：OVV-Drive-IO 将改变肿瘤免疫治疗的游戏规则</title>
    <updated>2021-01-02T09:45:39+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-02:/s/WFbm2XnSgaF_lu6g1YQckg</id>
    <link href="https://mp.weixin.qq.com/s/WFbm2XnSgaF_lu6g1YQckg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>正式启动！2021年不可多得的细胞基因免疫治疗技术专场盛会有哪些精彩看点？</title>
    <updated>2021-01-02T09:45:39+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-02:/s/TQP2UC5aky50lah_ZZjS3Q</id>
    <link href="https://mp.weixin.qq.com/s/TQP2UC5aky50lah_ZZjS3Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>PD-1 后来者寒冬已至？</title>
    <updated>2021-01-01T09:01:04+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-01:/s/JBzgKdpP6Q448p8KBDsdhQ</id>
    <link href="https://mp.weixin.qq.com/s/JBzgKdpP6Q448p8KBDsdhQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>佰傲谷陪你走过的2020：年度好文回顾</title>
    <updated>2021-01-01T09:01:04+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-01:/s/2Lmve-2ePK85Iql2N7K5pg</id>
    <link href="https://mp.weixin.qq.com/s/2Lmve-2ePK85Iql2N7K5pg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>8天！或成破纪录最快审批！国药集团新冠灭活疫苗中国上市</title>
    <updated>2020-12-31T11:14:52+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-31:/s/Ox3ywcKuXXZ0EaWhC0CmZA</id>
    <link href="https://mp.weixin.qq.com/s/Ox3ywcKuXXZ0EaWhC0CmZA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>佰傲谷发布|卫健委重磅新规：PD-1在对应适应症不需靶点检测！</title>
    <updated>2020-12-31T11:14:52+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-31:/s/Zu9cAWX1kF2eoLy9ZOBFXQ</id>
    <link href="https://mp.weixin.qq.com/s/Zu9cAWX1kF2eoLy9ZOBFXQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>官宣 | 启愈生物Q-1802临床申请获国家药审中心受理</title>
    <updated>2020-12-30T12:15:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-30:/s/oGM29N2hMSuKGV_oz6iB7w</id>
    <link href="https://mp.weixin.qq.com/s/oGM29N2hMSuKGV_oz6iB7w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>百济神州TIGIT单抗接连获批三种癌症临床适应症</title>
    <updated>2020-12-30T12:15:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-30:/s/55JkDZcx5bRqRZCHIXtN8w</id>
    <link href="https://mp.weixin.qq.com/s/55JkDZcx5bRqRZCHIXtN8w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>瑞博生物IPO获受理：或成科创板小核酸第一股</title>
    <updated>2020-12-30T12:15:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-30:/s/9c-mZupMkfINmOoYjtgp1Q</id>
    <link href="https://mp.weixin.qq.com/s/9c-mZupMkfINmOoYjtgp1Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>保护效力79.34%，国药中生北京发布新冠灭活疫苗III期临床中期分析结果</title>
    <updated>2020-12-30T12:15:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-30:/s/SdJIgEEuzAqzfsq19zZtFw</id>
    <link href="https://mp.weixin.qq.com/s/SdJIgEEuzAqzfsq19zZtFw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Immunity颠覆性结果！新冠病人PD-1阳性CD8T细胞IFN-γ分泌能力更强</title>
    <updated>2020-12-30T12:15:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-30:/s/7IIXP9nXHxq3P7Fdutwr3w</id>
    <link href="https://mp.weixin.qq.com/s/7IIXP9nXHxq3P7Fdutwr3w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>安斯泰来基因疗法一年报告三起死亡病例，FDA竟解除了临床禁制</title>
    <updated>2020-12-29T12:07:11+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-29:/s/cnETIzAvPIOTjv7UQk-WzQ</id>
    <link href="https://mp.weixin.qq.com/s/cnETIzAvPIOTjv7UQk-WzQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>分子互作研发利器SPR技术-药典指定亲和力测定技术</title>
    <updated>2020-12-29T12:07:11+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-29:/s/Su4gRF8lER6aQMflw1b-wQ</id>
    <link href="https://mp.weixin.qq.com/s/Su4gRF8lER6aQMflw1b-wQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>国内首个申报临床的Claudin 18.2双抗获NMPA受理</title>
    <updated>2020-12-29T12:07:11+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-29:/s/OTdjgXuETR10CKszKKYYmg</id>
    <link href="https://mp.weixin.qq.com/s/OTdjgXuETR10CKszKKYYmg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>《治疗用生物制品病毒污染风险控制要点》发布在即！</title>
    <updated>2020-12-28T11:01:01+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-28:/s/vXClF7ZzwgxvDNaggbvA6Q</id>
    <link href="https://mp.weixin.qq.com/s/vXClF7ZzwgxvDNaggbvA6Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>国产PD1全部成功进入医保</title>
    <updated>2020-12-28T11:01:01+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-28:/s/XWdBAMxvidvRo7voihNtcA</id>
    <link href="https://mp.weixin.qq.com/s/XWdBAMxvidvRo7voihNtcA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>当你在提质粒，未来科技如何制造生物药？</title>
    <updated>2020-12-28T11:01:01+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-28:/s/4eaG4KkLOwuYNc5a7RL_Ng</id>
    <link href="https://mp.weixin.qq.com/s/4eaG4KkLOwuYNc5a7RL_Ng" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>